Abstract:Introduction: Machine learning (ML) algorithms and statistical modeling offer a potential solution to offset the challenge of diagnosing early Alzheimer's disease (AD) by leveraging multiple data sources and combining information on neuropsychological, genetic, and biomarker indicators. Among others, statistical models are a promising tool to enhance the clinical detection of early AD. In the present study, early AD was diagnosed by taking into account characteristics related to whether or not a patient was taking specific drugs and a significant protein as a predictor of Amyloid-Beta (Aβ), tau, and ptau [AT(N)] levels among participants. Methods: In this study, the optimization of predictive models for the diagnosis of AD pathologies was carried out using a set of baseline features. The model performance was improved by incorporating additional variables associated with patient drugs and protein biomarkers into the model. The diagnostic group consisted of five categories (cognitively normal, significant subjective memory concern, early mildly cognitively impaired, late mildly cognitively impaired, and AD), resulting in a multinomial classification challenge. In particular, we examined the relationship between AD diagnosis and the use of various drugs (calcium and vitamin D supplements, blood-thinning drugs, cholesterol-lowering drugs, and cognitive drugs). We propose a hybrid-clinical model that runs multiple ML models in parallel and then takes the majority's votes, enhancing the accuracy. We also assessed the significance of three cerebrospinal fluid biomarkers, Aβ, tau, and ptau in the diagnosis of AD. We proposed that a hybrid-clinical model be used to simulate the MRI-based data, with five diagnostic groups of individuals, with further refinement that includes preclinical characteristics of the disorder. The proposed design builds a Meta-Model for four different sets of criteria. The set criteria are as follows: to diagnose from baseline features, baseline and drug features, baseline and protein features, and baseline, drug and protein features. Results: We were able to attain a maximum accuracy of 97.60% for baseline and protein data. We observed that the constructed model functioned effectively when all five drugs were included and when any single drug was used to diagnose the response variable. Interestingly, the constructed Meta-Model worked well when all three protein biomarkers were included, as well as when a single protein biomarker was utilized to diagnose the response variable. Discussion: It is noteworthy that we aimed to construct a pipeline design that incorporates comprehensive methodologies to detect Alzheimer's over wide-ranging input values and variables in the current study. Thus, the model that we developed could be used by clinicians and medical experts to advance Alzheimer's diagnosis and as a starting point for future research into AD and other neurodegenerative syndromes.

Bayesian Network Modelling for the Clinical Diagnosis of Alzheimer’s Disease

Bayesian Network Modelling for the Clinical Diagnosis of Alzheimer's Disease

Attention-based and Micro Designed EfficientNetB2 for Diagnosis of Alzheimer’s Disease

Deep Neural Network Classifier for Alzheimer’s Disease

A multilayer multimodal detection and prediction model based on explainable artificial intelligence for Alzheimer’s disease

Using Multi-Scale Genetic, Neuroimaging and Clinical Data for Predicting Alzheimer’s Disease and Reconstruction of Relevant Biological Mechanisms

Early Detection Models for Persons with Probable Alzheimer's Disease with Deep Learning

Heterogeneous multimodal biomarkers analysis for Alzheimer's disease via Bayesian network

Development of a robust parallel and multi-composite machine learning model for improved diagnosis of Alzheimer's disease: correlation with dementia-associated drug usage and AT(N) protein biomarkers

Bayesian deep neural networks for low-cost neurophysiological markers of Alzheimer's disease severity

A Single Model Deep Learning Approach for Alzheimer’s Disease Diagnosis

Application of artificial neural network model in diagnosis of Alzheimer's disease

Forecasting the Progression of Alzheimer's Disease Using Neural Networks and a Novel Pre-Processing Algorithm

Bayesian inference and role of astrocytes in amyloid-beta dynamics with modelling of Alzheimer's disease using clinical data

Brain Networks Modeling for Studying the Mechanism Underlying the Development of Alzheimer’s Disease

A Single Model Deep Learning Approach for Alzheimer's Disease Diagnosis

A Study on the Prediction of Questionable Dementia Using Bayesian Network

Updated Models of Alzheimer's Disease with Deep Neural Networks

An explainable machine learning approach for Alzheimer's disease classification

c-Diadem: a constrained dual-input deep learning model to identify novel biomarkers in Alzheimer's disease

Prediction of Conversion from Mild Cognitive Impairment to Alzheimer Disease Based on Bayesian Data Mining with Ensemble Learning.